|
PF-28923 |
ONEMER 30 mg/ mL solucion inyectable |
2007-10-07 |
|
Laboratorios Pisa S.A. de C.V. |
Mexico
|
Pisa De Guatemala, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-29009 |
NOVACAREL 400 MG/4 ML solucion inyectable |
2007-10-21 |
|
Laboratorios Pisa S.A. de C.V. |
Mexico
|
Pisa De Guatemala, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-29010 |
Solucion HM Pisa Concetrado Acido para Hemodialisis Sin Potasio |
2007-10-21 |
|
Laboratorios Pisa S.A. de C.V. |
Mexico
|
Pisa De Guatemala, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-29011 |
Solucion HM Pisa Concetrado Acido para Hemodialisis Con Potasio |
2007-10-21 |
|
Laboratorios Pisa S.A. de C.V. |
Mexico
|
Pisa De Guatemala, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-29024 |
ISOFLURANO PISA 100 mL solucion para inhalacion |
2007-10-22 |
|
Laboratorios Pisa S.A. de C.V. |
Mexico
|
Pisa De Guatemala, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-19085 |
HIDRAVIDA PEDIATRICO SOLUCION ORAL |
2007-11-13 |
|
Laboratorios Pisa S.A. de C.V. |
Mexico
|
Pisa De Guatemala, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-29551 |
GRATEN 2.5 mg/ 2.5 mL solucion inyectable |
2023-01-20 |
|
Laboratorios Pisa S.A. de C.V. |
Mexico
|
Almar Médica |
Servicio De Comercio Internacional |
Almar Diagnóstica |
Pisa Farmacéutica de Guatemala |
Droguería Repremedh Representaciones Médicas Hospitalarias |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-29552 |
GRATEN HP 50 mg/ 2 mL solucion inyectable |
2008-01-20 |
|
Laboratorios Pisa S.A. de C.V. |
Mexico
|
Pisa De Guatemala, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-29624 |
LEVAMIN NORMO CON ELECTROLITOS solucion inyectable |
2008-02-05 |
|
Laboratorios Pisa S.A. de C.V. |
Mexico
|
Pisa De Guatemala, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-19136 |
BICARNAT 7.5% Solución inyectable |
2027-10-03 |
|
Laboratorios Pisa S.A. de C.V. |
Mexico
|
Almar Médica |
Servicio De Comercio Internacional |
Almar Diagnóstica |
Pisa Farmacéutica de Guatemala |
Droguería Repremedh Representaciones Médicas Hospitalarias |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|